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Background: Abnormal thyroid status has been reported in cystic fibrosis (CF) patients, and this can possibly be correlated to
neuromuscular symptoms. Iodothyronine deiodinase type 1 (D1) activity is an important determinant of thyroid status, and we chose to
investigate D1 activity in CF liver. Methods: We have measured hepatic D1 activities in two DF508 CF mouse models. Results: Hepatic D1
activity was significantly reduced by 31% to 48% in homozygous DF508 mice compared with wild-type genotypes. Conclusions: A
decreased hepatic D1 activity could be the biochemical basis of some of the abnormal thyroid parameters observed in cystic fibrosis patients.
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Progressive destruction of lung tissue due to recurrent
endobronchial infections still is the main cause of morbidity
and mortality in cystic fibrosis (CF) patients. In the past
three decades, however, a number of studies have reported
on an increased incidence of abnormal thyroid gland
function and thyroid status in CF. Subclinical hypothyroid-
ism, a condition characterized by elevated plasma levels of
the pituitary thyrotropic factor thyroid stimulating hormone
(TSH) with normal levels of circulating free thyroxine or
3,5,3V,5V-tetraiodothyronine (T4), has been reported to have
a higher incidence in CF patients [1,2]. Other observations
on thyroid parameters in cystic fibrosis vary although they
all consistently indicate an altered thyroid status. Decreased
serum T4 and 3,5,3V-triiodothyronine (T3) levels together1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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decreased serum T3 concentrations with normal T4 and
TSH levels [4] and normal T4 but elevated T3 concen-
trations [5]. Normal T4, T3 and TSH serum levels, but
increased levels of the biologically inactive metabolite
reverse T3 or 3,3V,5V-triiodothyronine (rT3), have been
measured in CF patients [6]; however, the latter observation
is not corroborated by the decreased serum rT3 levels
measured in CF patients with subclinical hypothyroidism
[1].
The main endocrine secretion of the human thyroid
gland is T4, generally believed to be a prohormone without
or with only few biological actions. An important meta-
bolic pathway of T4 is enzymatic deiodination by iodo-
thyronine deiodinase activity, in which one or more iodine
atoms are hydrolytically removed from the tyrosyl or inner
ring (3-/5-position) or from the phenolic or outer ring (3V-/
5V-position) of the iodothyronine molecule. The deiodinase
family consists of three members, each of which are
selenoenzymes with distinct substrate affinities and prefer-
ences for inner and/or outer ring deiodination [7,8]. Deio-
dinase type 1 (iodothyronine deiodinase type 1, D1), with
the highest activities in human liver and kidneys, plays a
central role in the monodeiodination of the outer ring of the
T4 molecule, converting the prohormone to the bioactiveed by Elsevier B.V. All rights reserved.
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minant of the systemic supply of T3 and thyroid status
[9,10].
In general, through their effects on, e.g., sarcolemmal
Na+, K+-ATPase and sarcoplasmic reticulum Ca2 +-ATPase
activities, thyroid hormones are important regulators of
skeletal muscle excitability and contractility [11,12]. It has
been suggested that subclinical hypothyroidism is involved
in neuromuscular symptoms such as muscle weakness and
myalgias and increased lactate levels during exercise [13–
17]. This correlates with the observed reduced oxidative
work performance in forearm muscle of cystic fibrosis
patients [18]. These neuromuscular symptoms could be
secondary to an altered thyroid status. More importantly,
perhaps, lung function and airway clearance in some cystic
fibrosis patients could possibly be improved with therapeu-
tic treatment aimed at restoring a normal thyroid status.
An altered hepatic D1 activity could explain some
aspects, e.g. decreased serum T3 and increased rT3 levels,
of the abnormal thyroid status in cystic fibrosis patients, as
has also been suggested by others [2,3,6,19]. We therefore
decided to investigate D1 activities in livers from two gene-
targeted CF mouse models.2. Material and methods
2.1. Mouse models
We have used two gene-targeted DF508 CF mouse
models: the cftrtm1Eur and the cftrtm2Cam mouse, developed
and described by van Doorninck et al. [20] and Colledge et
al. [21], respectively. Both mouse models have the DF508
mutation inserted in the cftr gene. The cftrtm1Eur mouse is
constructed using a double homologous recombination
procedure and contains no genomic alteration but the
DF508 mutation. The cftrtm2Cam mouse is developed using
a targeting construct containing the 3-bp deletion between
nucleotides 1522 and 1524, and a hypoxanthine phosphor-
ibosyl transferase (HPRT) mini-gene selection cassette in
intron 10 of the CFTR gene. Mice were bred at Erasmus
University, Rotterdam, The Netherlands (cftrtm1Eur) and in
the University of Sheffield Field Laboratories, Sheffield,
UK (cftrtm2Cam), respectively, and had free access to stan-
dard laboratory animal feed and water. Animal breeding and
use was approved by the local ethical review committees.
Adult animals were used; homozygous DF508 mice were
compared with wild-type littermates. Animals were killed
by cervical dislocation, after which, livers were quickly
excised, frozen in liquid nitrogen and then stored at  80
jC until further processing. Whole livers were homoge-
nized in 10-ml ice-cold buffered solution (250 mM sucrose,
1 mM dithiothreitol, pH 8.0) using an Ultra-Turrax and a
Potter–Elvehjem device. Homogenates were quickly frozen
in liquid nitrogen and stored at  80 jC until further
analysis.2.2. Materials
Reverse T3 (rT3) and 6-n-propyl-2-thiouracil (PTU) were
purchased from Sigma (St. Louis, MO). Sephadex LH-20
was from Amersham Pharmacia Biotech (Uppsala, Sweden).
Radioactively labeled [125I]-rT3 (24.4 TBq/mmol) was from
NEN Life Science Products (Boston, MA). Radiotracer was
purified on a 10 wt.%/vol.% Sephadex LH-20 column
shortly before use to remove free iodide as described earlier
[22]. The purified hormone fraction collected in the 0.5 M
NH3/ethanol eluate was evaporated at 37 jC under a nitrogen
atmosphere and then redissolved in the incubation medium.
Protein was measured according to Lowry et al. [23] using
BSA as a standard.
2.3. Iodothyronine deiodinase type 1 (D1)
Specific liver D1 (EC 3.8.1.4) activity was assayed in
duplicate by incubating 10 Ag liver homogenate protein for
15 min at 37 jC in 200 Al 100 mM phosphate buffer (pH
7.2), to which were added, 1 AM rT3, [125I]-rT3, to a
specific activity of 3 to 41014 cpm/mol rT3, 2 mM EDTA
and 10 mM dithiothreitol. The incubation was quenched by
adding 100 Al 5 wt.%/vol.% ice-cold BSA. Quenched
incubates were deproteinized with 500 Al 10 wt.%/vol.%
ice-cold trichloroacetic acid followed by precipitation of
denatured proteins at 1400 g (15 min, 4 jC). To 0.5 ml of
the supernatant thus obtained an equal volume of 0.1 M HCl
was added, and liberated iodide was separated from the
native iodothyronine with the use of Sephadex LH-20
column chromatography as described earlier [22], collecting
125I in the first four 1-ml 0.1 M HCl eluates. Non-specific
outer ring deiodination was determined in the presence of
100 AM PTU, a specific inhibitor of mammalian D1 activity.
The specific D1 activity was thus defined as the PTU-
sensitive outer ring deiodination of rT3 and was expressed
as fmol rT3 deiodinated/min/mg protein. Our calculations
included a correction factor of 2 to take into account the
random labeling of the 3V- and 5V-positions of [125I]-rT3.
2.4. Statistics
Data are presented as meansF S.D., with the number of
different preparations in parentheses. Statistical significance
was evaluated by Student’s t-test or Welch’s alternate t-test
[24], where appropriate. Statistical significance was accepted
at P < 0.05.
of Cystic Fibrosis 3 (2004) 125–1283. Results
No gross liver abnormalities in wild-type and homozy-
gous mutant mice were observed. Indeed, most gene-targeted
CF mice, cftr null mice, as well as DF508 homozygotes
(including the mouse models we have used), have no liver
and/or hepatobiliary pathologies reported [25]. The relative
Table 1
Specific hepatic D1 activities (in fmol/min/mg protein) in liver homoge-
nates from gene-targeted CF mouse models
Mouse strain Wild-type Homozygote
DF508/DF508
D (%) P
cftrtm1Eur 124F 24 (5) 86F 6 (5)  31 0.026
cftrtm2Cam 23F 6 (4) 12F 4 (5)  48 0.013
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expressed as a percentage of the wet organ weight, were
similar in both genotypes: 20F 5 (5) and 17F 3 (4)
(P= 0.33) in cftrtm2Cam wild-type and DF508 homozygote,
and 20F 3 (5) and 22F 2 (5) (P= 0.25) in cftrtm1Eur wild-
type and DF508 homozygote, respectively. These values
corroborate the absence of gross pathology, e.g., cirrhosis,
or altered protein synthesis in CF mouse livers, and validate
our calculations where enzyme activities were normalized
for the protein content of the preparation.
Table 1 shows that the hepatic specific D1 activity in
homozygote DF508 mice from both strains was reduced
by 31% to 48% compared to the respective wild-type
genotypes.4. Discussion
Based on our observations, we suggest that a decreased
hepatic D1 activity is the biochemical basis of some of the
abnormal thyroid parameters in human cystic fibrosis
patients.
The decreased activity of the selenoenzyme D1 could be
secondary to intestinal malabsorption and low serum levels
of the trace element selenium. Whole body analysis, how-
ever, only hinted at reduced selenium levels in a small group
(n = 4) of animals from the cftrtm1UNC knockout mouse
strain [26]. Human data on serum selenium are even more
equivocal: some studies report on decreased plasma seleni-
um levels in cystic fibrosis patients [27–32], whereas others
report serum selenium levels comparable to, or higher than,
healthy subjects [28,32,33]. Shwachman clinical scores and
whole blood selenium levels correlated negatively (i.e.,
patients with the highest clinical score possessed the lowest
selenium concentration) in the study by Lloyd-Still and
Ganther [32]. The reported differences in plasma selenium
levels could well be related to differences in the nutritional
status of individual CF patients.
Upon severe selenium deficiency, hepatic D1 activity in
rat is decreased, although liver selenium levels and D1
activities do not tightly correlate [34]. In addition, in
severely selenium deficient rats the drastically reduced
hepatic D1 activities were not reflected in the moderate
changes measured in thyroid hormone levels [35–37].
Plasma and liver selenium levels are poor predictors of
circulating thyroid hormone concentrations.
We do not know of other reported data on direct measure-
ments of D1 activity in CF. Still, the complex relationshipbetween serum selenium levels in CF and selenoenzyme
activity can be illustrated by the selenocysteine-containing
enzyme, glutathione peroxidase (GSH-Px). In erythrocytes
of 68 CF patients, the average GSH-Px activity was reduced
by 20%, and this correlated positively with the reduced
average plasma selenium level (D = 24%) [28]. Contrary,
the average GSH-Px activity in a group of 20 CF patients
was found to be in the normal range despite the low average
whole blood selenium level which was drastically reduced
by more than 40% [32]. Moreover, the GSH-Px activities
measured individually correlated only weakly with the whole
blood selenium levels in these patients. Castillo et al. [33]
reported low serum selenium concentrations together with
normal GSH-Px activities in a subset of CF patients with low
serum tocopherol (vitamin E) levels. Normal selenium and
GSH-Px parameters were established by these authors in
patients with normal serum tocopherol levels. Concomitantly,
reduced plasma selenium and tocopherol levels in CF were
also measured by others [29,38]. This could indicate that the
nutritional status is an important determinant in selenium
availability and selenoenzyme, i.e., deiodinase, activity.
Initial results from this study were presented at the 27th
Annual Meeting of the European Thyroid Association in
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